Skip to content

US · ACHV · BIOTECHNOLOGY

Achieve Life Sciences, Inc. (ACHV) intrinsic value and stock valuation

$6.78as of 2026-11-21 · Mkt cap 683.71M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Achieve Life Sciences, Inc. DCF and intrinsic value

InvestorsCraft values ACHV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACHV’s statements →

Achieve Life Sciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bothell, WA 98021 achievelifesciences.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-54.65M
20112025
Free cash flow
-$-49.47M
20112025
Total equity
$21.5M-10.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-54.88M-$-39.07M-$-27.25M-$-40.8M-$-33.09M
Net income-$-54.65M-$-39.83M-$-29.82M-$-42.35M-$-33.15M
EPSd-$-1.25M-$-1.24M-$-1.5M-$-4M-$-4.08M
Operating cash flow-$-49.47M-$-29.77M-$-24.48M-$-37.57M-$-29.44M
Capital expenditure-$0.00$0.00-$-20K$0.00$0.00
Free cash flow-$-49.47M-$-29.77M-$-24.5M-$-37.57M-$-29.44M
Total assets$41.8M$38.6M$19.4M$30M$47.5M
Total debt$15M$9.96M$16.7M$16.2M$15M
Net debt-$-5.97M-$-2.77M$1.19M-$-8.52M-$-28.03M
Total equity$21.5M$20.9M-$-1.45M$8.3M$28M
Cash and short-term investments$36.4M$34.3M$15.6M$24.7M$43M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$230K$230K$0.00$0.00$0.00
Gross profit-$-230K-$-230K$0.00$0.00$0.00
Research and development expenses$23M$22.8M$15.8M$30.1M$24M
Selling, general and administrative expenses$31.9M$16.3M$11.4M$10.7M$9.13M
Other expenses$50K-$-230K$0.00$0.00$0.00
Operating expenses$54.7M$38.8M$27.3M$40.8M$33.1M
Cost and expenses$54.9M$39.1M$27.3M$40.8M$33.1M
Interest income$1.5M$2.36M$820K$200K$20K
Interest expense$820K$2.18M$2.85M$1.79M$0.00
Depreciation and amortization$230K$230K$230K$240K$250K
Ebitda-$-53.6M-$-37.42M-$-26.73M-$-40.33M-$-32.9M
Operating income-$-54.88M-$-39.07M-$-27.25M-$-40.8M-$-33.09M
Total other income/expenses, net$230K-$-760K-$-2.56M-$-1.55M-$-60K
Income before tax-$-54.65M-$-39.83M-$-29.82M-$-42.35M-$-33.15M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-54.65M-$-39.83M-$-29.82M-$-42.35M-$-33.15M
Weighted average shares outstanding$43.6M$32.1M$19.8M$10.6M$8.12M
Weighted average diluted shares outstanding$43.6M$32.1M$19.8M$10.6M$8.12M
Balance sheet
20252024202320222021
Cash and short-term investments$36.4M$34.3M$15.6M$24.7M$43M
Net receivables$0.00$0.00$110K$100K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$39.9M$36.5M$17M$27.3M$44.6M
Property, plant and equipment, net$60K$120K$80K$120K$60K
Goodwill and intangible assets$1.78M$2.01M$2.23M$2.45M$2.67M
Long-term investments$20K$0.00$50K$0.00$0.00
Total non-current assets$1.9M$2.17M$2.39M$2.64M$2.92M
Total assets$41.8M$38.6M$19.4M$30M$47.5M
Accounts payable$870K$1.95M$620K$1.66M$840K
Short-term debt$3.77M$60K$16.7M$16.1M$70K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.08M$6.68M$20.8M$21.6M$4.55M
Long-term debt$11.2M$9.9M$10K$70K$14.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.2M$11.1M$10K$70K$14.9M
Capital lease obligations$60K$120K$70K$130K$70K
Total liabilities$20.3M$17.7M$20.8M$21.7M$19.5M
Common stock$120K$100K$90K$90K$80K
Retained earnings-$-260.23M-$-205.58M-$-165.75M-$-135.94M-$-93.59M
Accumulated other comprehensive income (loss)$10K$30K$0.00$0.00$0.00
Total equity$21.5M$20.9M-$-1.45M$8.3M$28M
Total investments$15.5M$21.6M$50K$0.00$0.00
Total debt$15M$9.96M$16.7M$16.2M$15M
Net debt-$-5.97M-$-2.77M$1.19M-$-8.52M-$-28.03M
Cash flow statement
20252024202320222021
Net income-$-54.65M-$-39.83M-$-29.82M-$-42.35M-$-33.15M
Depreciation and amortization$230K$230K$230K$240K$250K
Stock-based compensation$8.76M$5.33M$3.44M$3.27M$2.19M
Change in working capital-$-4.27M$2.41M-$-780K$80K$1.23M
Accounts receivable$0.00$110K$0.00$50K-$-150K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.08M$1.33M-$-1.04M$800K$510K
Net cash provided by operating activities-$-49.47M-$-29.77M-$-24.48M-$-37.57M-$-29.44M
Investments in property, plant and equipment-$0.00$0.00-$-20K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$6.11M-$-21.58M-$-20K$0.00$0.00
Common stock issued$46.5M$56.1M$15.3M$19.2M$21.3M
Common stock repurchased$0.00$0.00-$-30K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$51.5M$48.5M$15.3M$19.3M$36.6M
Net change in cash$8.18M-$-2.79M-$-9.22M-$-18.25M$7.17M
Cash at end of period$21M$12.8M$15.6M$24.8M$43.1M
Operating cash flow-$-49.47M-$-29.77M-$-24.48M-$-37.57M-$-29.44M
Capital expenditure-$0.00$0.00-$-20K$0.00$0.00
Free cash flow-$-49.47M-$-29.77M-$-24.5M-$-37.57M-$-29.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Achieve Life Sciences, Inc.

        Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

        CEO
        Andrew D. Goldberg
        Employees
        28
        Beta
        2.22

        Explore

        Frequently asked questions

        What is the intrinsic value of Achieve Life Sciences, Inc. (ACHV)?

        InvestorsCraft does not currently publish an intrinsic value for ACHV. How the IC value is calculated.

        Is ACHV undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACHV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.